Tag: biosimilar monoclonal antibodies market analysis

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

How Much Growth is Expected for the Biosimilar Monoclonal Antibodies Market from 2024 to 2033?

In the recent past, the biosimilar monoclonal antibodies market has witnessed unprecedented growth. By 2024, it is predicted to reach $9.25 billion from a previous $8.04 billion in 2023, which is a compound annual growth rate (CAGR) of 15.1%. This significant growth during the historic period is accounted for by factors such as patent expiry, increased familiarity with biosimilars, government interventions, rising investments from pharmaceutical firms, and escalating acceptance and use of biosimilars by clinicians and patients.

The market size of biosimilar monoclonal antibodies is projected to expand swiftly in the coming years, reaching a worth of $12.79 billion in 2028 with a compound annual growth rate (CAGR) of 8.5%. This projected growth during the forecast period can be linked to factors such as the increase in biologic expenditures, the expansion of the biosimilar portfolio, the personalization of biosimilar therapies, and growing public engagement with biosimilars. Notable trends expected during this forecast period include the expansion of therapeutic options, the personalization of biosimilars, collaborations and partnerships within the industry, the adoption of biosimilar autoinjectors and devices, and the introduction of biobetters.

Claim Your Free Sample of the Global Biosimilar Monoclonal Antibodies Market Report Today!

https://www.thebusinessresearchcompany.com/sample.aspx?id=3412&type=smp

What Factors Are Encouraging Growth in the biosimilar monoclonal antibodies Market?

The anticipation of heightened chronic disease rates is likely to fuel the progression of the biosimilar monoclonal antibodies sector. Biosimilar monoclonal antibodies are typically utilized in the treatment of enduring diseases such as cancer, autoimmune disorders, and rheumatoid arthritis. Numerous cancer treatments utilize the biosimilars of monoclonal antibodies such as trastuzumab, bevacizumab, and rituximab. Furthermore, cancer incidence continues to heighten annually. As documented by the US-based National Library of Medicine, National Center for Biotechnology Information (NCBI) in January 2023, projections show a 99.5% increase in citizens aged 50 and over with at least one chronic illness by 2050, escalating from 71.522 million in 2020 to 142.66 million. Consequently, the growing prevalence of chronic diseases is anticipated to propel the development of the biosimilar monoclonal antibodies industry.

Which Segments Play a Vital Role in the Biosimilar Monoclonal Antibodies Market?

1) By Type: Synthetic Chemicals, Biopharmaceuticals, Other Types

2) By Compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab

3) By Application: Chronic & Autoimmune Diseases, Oncology, Other Applications

What Trends Are Driving Change in the Biosimilar Monoclonal Antibodies Market?

Take for instance, in July 2021, a partnership was forged between Abzena, a biologics and bioconjugates research organization in the US, and BioXpress Therapeutics to facilitate third-party clients with biosimilar development. The focus of this collaboration is to provide companies manufacturing biosimilar medicines with a comprehensive path that includes counsel on design, cell line and process development and both clinical and commercial GMP manufacturing. This partnership has the potential to expedite the drug development timeline in the biosimilars industry. BioXpress Therapeutics and Abzena bring complementary strengths to the table, offering a flexible and creative approach spanning from niche biosimilar development to large-scale production.

Order Now for Fast Delivery of Your Biosimilar Monoclonal Antibodies Market Report!

https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodie-global-market-report

What Regions Are Contributing Significantly to the Growth of the Biosimilar Monoclonal Antibodies Market?

North America was the largest region in the biosimilar monoclonal antibodies market in 2023. The regions covered in the biosimilar monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The Biosimilar Monoclonal Antibodies Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the biosimilar monoclonal antibodies market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Biosimilar Monoclonal Antibodies Market Include

1. Biosimilar Monoclonal Antibodies Market Executive Summary

2. Biosimilar Monoclonal Antibodies Market Segments

3. Biosimilar Monoclonal Antibodies Market Size And Template Market Growth Rate

4. Key Biosimilar Monoclonal Antibodies Market Trends

5. Major Biosimilar Monoclonal Antibodies Market Drivers

……

25. Key Mergers And Acquisitions In The Biosimilar Monoclonal Antibodies Market

26. Top Biosimilar Monoclonal Antibodies Companies

27. Biosimilar Monoclonal Antibodies Market Opportunities And Strategies

28. Biosimilar Monoclonal Antibodies Market, Conclusions And Recommendations

29. Appendix

Discover Related Reports by The Business Research Company:

Biologics CDMO Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Pharmaceutical API Manufacturing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pharmaceutical-api-manufacturing-global-market-report

Anti-Asthmatics And COPD Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

As per The Business Research Company’s Biosimilar Monoclonal Antibodies Global Market Report 2024, the biosimilar monoclonal antibodies market is expected to show significant growth in the forecast period.

The biosimilar monoclonal antibodies market has experienced remarkable growth in recent years, indicative of the increasing demand for advanced therapeutic options. Let’s dissect the driving forces behind this growth and what the future holds for this dynamic sector.

Current Landscape and Growth Dynamics

• The biosimilar monoclonal antibodies market has surged from $8.04 billion in 2023 to $9.25 billion in 2024, boasting a compound annual growth rate (CAGR) of 15.1%.
• This growth spurt can be attributed to patent expirations, heightened awareness of biosimilars, government initiatives, increased investment from pharmaceutical companies, and the growing acceptance of biosimilars among clinicians and patients.

Forecasts and Future Trends

• The market is poised for further expansion, projected to reach $12.79 billion by 2028, with a compound annual growth rate (CAGR) of 8.5%.
• Factors driving growth in the forecast period include rising biologic expenditure, expansion of biosimilar portfolios, personalization of biosimilar therapy, and heightened public interest in biosimilars.
• Major trends on the horizon encompass therapeutic expansion, personalized biosimilars, collaborations and partnerships, biosimilar autoinjectors and devices, and the emergence of biobetters.

Rising Prevalence of Chronic Diseases Fuels Growth in the Biosimilar Monoclonal Antibodies Market

• The prevalence of chronic diseases, including cancer, autoimmune diseases, and rheumatoid arthritis, is expected to be a key driver of the biosimilar monoclonal antibodies market.
• Biosimilar monoclonal antibodies play a pivotal role in treating chronic diseases, with notable examples including trastuzumab, bevacizumab, and rituximab in cancer treatment.
• The incidence of cancer is on the rise, contributing to the escalating demand for effective therapeutic interventions, thereby driving market growth.

View More On The Biosimilar Monoclonal Antibodies Market Report 2024 – https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodie-global-market-report

Enzene Biosciences Launches Cetuximab Biosimilar for Cancer Therapy

• Major players in the biosimilar monoclonal antibody market are focusing on developing biosimilar versions of therapeutic chimeric monoclonal antibodies to broaden treatment options and offer cost-effective alternatives for various conditions.
• Enzene Biosciences Ltd. introduced Cetuximab, a biosimilar of the cancer drug Erbitux, in May 2021, aimed at treating metastatic colorectal cancer and head and neck cancer.
• The use of a Chinese Hamster Ovary (CHO) cell line in manufacturing Cetuximab has resulted in more human-like glycosylation patterns, potentially reducing adverse effects.

Biocon Biologics Ltd. Acquires Viatris Inc.’s Biosimilars Business to Strengthen Global Presence

• In November 2022, Biocon Biologics Ltd. expanded its footprint in the biosimilars market by acquiring Viatris Inc.’s biosimilars business, enhancing its global reach and commercial capabilities.
• This strategic acquisition enables Biocon Biologics to leverage Viatris Inc.’s commercial infrastructure and research and development expertise to cater to diverse market segments.
• Viatris Inc., a prominent player in the pharmaceutical industry, develops, licenses, manufactures, and distributes generic and branded medicines.

Segmentation and Regional Insights

• The biosimilar monoclonal antibodies market is segmented by type, compound, and application, reflecting its multifaceted nature and diverse therapeutic applications.
• North America emerged as the largest region in the biosimilar monoclonal antibodies market in 2023, signaling the region’s prominence in this sector.

Conclusion: Navigating the Promising Trajectory
The biosimilar monoclonal antibodies market presents an exciting landscape characterized by innovation, collaboration, and expanding treatment options. As stakeholders continue to invest in research and development and forge strategic partnerships, the journey toward addressing chronic diseases and improving patient outcomes is poised to achieve new milestones in the years ahead.

Request A Sample Of The Global Biosimilar Monoclonal Antibodies Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=3412&type=smp